NRC-2694-A + Paclitaxel
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma
Conditions
Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Trial Timeline
Sep 30, 2022 → Jun 30, 2027
NCT ID
NCT05283226About NRC-2694-A + Paclitaxel
NRC-2694-A + Paclitaxel is a phase 2 stage product being developed by Natco Pharma for Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05283226. Target conditions include Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05283226 | Phase 2 | Recruiting |
Competing Products
20 competing products in Carcinoma